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Abstract: A novel nanocarrier system was designed and developed with key components 
uniquely structured at the nanoscale for early cancer diagnosis and treatment. In order to per-
form magnetic resonance imaging, hydrophilic superparamagnetic maghemite nanoparticles 
(NPs) were synthesized and coated with a lipophilic organic ligand. Next, they were entrapped 
into polymeric NPs made of biodegradable poly(lactic-co-glycolic acid) linked to polyethylene 
glycol. In addition, resulting NPs have been conjugated on their surface with a 2,2′-(7-(4-((2-
aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid ligand for 
subsequent 68Ga incorporation. A cell-based cytotoxicity assay has been employed to verify 
the in vitro cell viability of human pancreatic cancer cells exposed to this nanosystem. Finally, 
in vivo positron emission tomography-computerized tomography biodistribution studies in 
healthy animals were performed.
Keywords: maghemite nanoparticles, organic coating, polymeric nanoparticles, magnetic 
resonance imaging, radiolabeling, positron emission tomography
Introduction
Despite impressive progress in basic and clinical medicine, cancer still ranks as one 
of the leading causes of mortality in Europe and in the United States.1,2 Consequently, 
the development of imaging agents and diagnostic methods for detecting cancer at an 
early presymptomatic stage as well as new therapeutic agents able to overcome the 
problems commonly associated with traditional treatments is urgently required.
Cancer diagnosis utilizes anatomical or molecular imaging methods such as mag-
netic resonance imaging (MRI), positron emission tomography (PET), single photon 
emission computerized tomography (CT), ultrasound imaging, optical imaging. Each 
of these modalities has its own limitations in terms of spatial resolution, sensitivity, 
and depth of signal penetration that might be overcome by the combination of two 
or more such modalities.3 Therefore, dual or multimodal imaging are currently being 
explored to enhance the quality and specificity of imaging methods in order to achieve 
proper visualization of organs or to better localize the accumulation of a diagnostic 
or therapeutic agent. Concomitantly, the development of multimodal imaging probes 
has attracted much attention during the last years.
Recently, nanotechnology has emerged as an excellent tool for the generation of 
nanoparticles (NPs) for diagnostic (imaging) or therapeutic purposes. Among all NPs, 
inorganic ones have attracted great interest, given their intrinsic physical properties and 
compatible size. The best example can be found in magnetic NPs (MNPs) which have 
been used as contrast agents for MRI for more than 20 years.4 However, the pursuit of 
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multimodal imaging agents requires the development of organic 
ligands that are able to make the MNPs lipophilic (coated with 
an organic molecule), and that entrap them into a polymeric 
matrix acting as a targetable water soluble nanocarrier. In ideal 
planning, this nanocarrier would be further functionalized with 
an appropriate labeling agent (eg, a positron emitter), to allow 
multi-modal in vivo imaging. In order to achieve efficient 
distributions in the targeted tumor lesions for early cancer 
diagnosis and treatment, the colloidal nanocarriers are required 
to be highly monodisperse and smaller than 200 nm.5
Here we describe the preparation and characterization 
of a novel, versatile, and biocompatible hybrid nanocarrier 
for dual PET/MRI imaging. This nanocarrier contains a 
superparamagnetic maghemite core consisting of crystalline, 
as well as hydrophilic and strongly positively charged ceric 
ammonium nitrate (CAN)-stabilized maghemite NPs for 
MRI contrast,6 which were encapsulated in the well-known 
poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol) 
copolymer (PLGA-b-PEG-COOH). Polyethyleneglycol 
(PEG)-based polymeric nanoparticles (PNPs), owing to 
their stealth character,7 are widely used delivery systems for 
in vivo applications. On the other hand, the PLGA-b-PEG-
COOH copolymer self-assembles to form targetable PNPs 
consisting of a hydrophobic poly(D,L-lactide-co-glycolide) 
(PLGA) core and a hydrophilic PEG corona-like shell. Inter-
estingly, the presence of active sites (COOH) on the surface 
allows surface modification with 2,2′-(7-(4-((2-aminoethyl)
amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)
diacetic acid (NODA) to chelate 68Ga for PET imaging (see 
Figure 1 for the schematic representation of the fabrication 
of this nanocarrier). Since the resulting composite presented 
a high T
2
 relaxivity, such a system should be suitable as an 
MRI contrast agent. Furthermore, the 68Ga-radiolabeled 
NPs proved to be stable and allowed in vivo biodistribution 
studies in healthy animals using PET-CT. Further attachment 
of functional groups that can act as targeting moieties or 
therapeutic agents could be pursued in the near future using 
the functional groups present on the NP surface, leading to 
multimodal PET-MRI diagnostic agents. The combination 
of both PET and MRI imaging capabilities should provide 
images with high anatomical resolution of MRI at the sensi-
tivity of PET (10−9 to 10−12 M).8
Despite the suitability of the nanoplatforms reported 
here for the preparation of a wide range of diagnostic mul-
timodal agents, one first application is expected in the field 
of pancreatic cancer diagnosis in the frame of the SaveMe 
project (EU-FP7 project number CP-IP 263307-2). Thus, 
a preliminary investigation (in vitro toxicity tests) of the 
developed nanosystem has been performed.
An application to pancreatic ductal adenocarcinoma 
(PDAC) has been preliminarily investigated. PDAC is one 
of the most aggressive malignancies with an overall 5-year 
survival rate of only 3%–5% and a median survival time after 
diagnosis of 6 months.9 This highly lethal disease is usually 
diagnosed in an advanced stage when there are few or no 
effective therapies available.10
Materials and methods
All chemicals were purchased from Sigma-Aldrich (St 
Louis, MO, USA) and used as received. Poly(D,L-lactide-
co-glycolide) (50/50) with carboxylic acid end group 
(PLGA-COOH, pharmaceutical grade, inherent viscosity 
0.12 dL/g, molecular weight (MW) ∼7 kDa) was purchased 
from Lakeshore Biomaterials (Lakeshore Biomaterials, Inc, 
Birmingham, AL, USA). PEG with amino and carboxylic 
acid end groups (NH
2
-PEG-COOH, .95%, MW ∼3 kDa) 
was purchased from Rapp Polymere GmbH (Tübingen, 
Germany). All aqueous solutions were prepared with deion-
ized water obtained using an ultrafiltration system (Milli-Q, 
Millipore Corporation, Billerica, MA, USA) with a mea-
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Figure 1 Schematic representation of the synthesis of Magh-1-PNPs-NODA.
Abbreviations: CAN, ceric ammonium nitrate; PNPs, polyethyleneglycol-based nanoparticles; NODA, 2,2′-(7-(4-((2-aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7-
triazonane-1,4-diyl)diacetic acid; PLGA-b-PEG, poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol).
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sured resistivity above 18 MΩ/cm (referred in the text as 
double distilled [dd] water). Tetrahydrofuran was distilled 
from sodium/benzophenone just prior to use and stored 
under Ar. CH
2
Cl
2
 and CHCl
3
 were passed through basic 
alumina prior to use. Transmission electron microscopy 
(TEM) was conducted on a JEOL JEM 2010 at 200 keV 
(JEOL, Tokyo, Japan). Samples for TEM analyses were 
prepared by spreading a small drop of the NP dispersion 
on amorphous carbon-coated copper grids (Formvar carbon 
400 mesh grids) followed by air-drying. Inductively coupled 
plasma (ICP) was performed on diluted acidic aqueous 
solutions using a Jobin Yvon Ultima 2 device (HORIBA, 
Ltd, Fukuoka, Japan). 1H-NMR (hydrogen-1 nuclear mag-
netic resonance) and 13C-NMR (carbon nuclear magnetic 
resonance) spectra were recorded using CDCl
3
 or dimethyl 
sulfoxide solutions at 300, 400, and 600 MHz for 1H, and 
75.46, 100.6, and 150.92 MHz for 13C. Chemical shifts (δ) 
are reported in ppm relative to CHCl
3
 (δ = 7.26 for 1H and 
δ = 77.0 for 13C). Fourier transform infrared spectra were 
recorded on a PerkinElmer Spectrum 2000 (PerkinElmer, 
Waltham, MA, USA). Dynamic light scattering (DLS) mea-
surements were performed on a Malvern Zetasizer nano-S 
working with a 532 nm laser beam (Malvern Instruments 
Ltd, Malvern, UK). Moreover, ζ potential measurements 
were conducted in DTS1060C-clear disposable zeta cells 
at 25°C. SpectraAA 100 Varian (Palo Alto, CA, USA) was 
used for atomic absorption spectroscopy analyses. Ther-
mogravimetric analyses were carried out on a TA Instru-
ments 1GA Q500 (TA Instruments, New Castle, DE, USA) 
apparatus (nitrogen flow, isothermal temperature accuracy 
of 0.1°C for a weighting precision of 0.1 µg).
Synthesis of ethyl 12-((3,4-dihydroxyphenethyl)amino)-
12-oxododecanoate 1 was conducted as reported in the steps 
2-4 of the supplementary material (see also Figures S2–S4).
Synthesis of Magh-1
CAN-maghemite NPs were synthesized according to a known 
procedure that was recently developed in our laboratory 
with slight modifications, using preformed magnetite NPs as 
starting nanoscale material (see supporting information for 
details concerning the all synthesis pathways).6
Accordingly, the original CAN-Magh solution was 
diluted with water and added to an ethanolic solution of ethyl 
12-([3,4-dihydroxyphenethyl]amino)-12-oxododecanoate 
(EDAO) 1. The mixture was sonicated in an ultrasound bath 
for 1 hour, and it was left to react overnight at room tempera-
ture under mechanical stirring. Afterward, the solution was 
decanted magnetically.
Synthesis of Magh-1-PNPs
A total of 560 mg of PLGA-b-PEG-COOH (10 kDa) 
was added to 56 mL of an acetone solution of Magh-1. 
The organic phase was mixed to 560 mL of ultrapure water 
under vigorous stirring, maintaining the water/organic 
ratio of 10/1 with constant removal of the solution. The 
mixture was kept for 30 minutes under vigorous stirring. 
The residual organic solvent was evaporated under reduced 
pressure. The solution was concentrated to a volume of 
100 mL using a tangential flow filter (Pellicon XL filter 
device, Biomax membrane with 500.000 NMWL; Millipore 
Corporation) following by filtration using a syringe filters 
SterivexTM-GP of polyethersulfone (0.22 µm, Millipore 
Corporation).
Synthesis of Magh-1-PNPs-NODA
The linkage of NODA on the surface of the particle was 
 carried out through a classic peptide formation. In  particular, 
Magh-1-PNP water solutions were stirred for 2 hours 
in the presence of 1-ethyl-3-(3-dimethylaminopropyl) 
 carbodiimide. Then, NODA-GA-ethylenediamine were 
added, and the reaction mixture was kept under stirring for 
an additional 2 hours. The particles were purified with a 
centrifugal filter device.
Nuclear magnetic resonance (NMR) 
relaxivity
Relaxivity measurements were performed on a Bruker 
Minispec TD-NMR system (Bruker Optik GmbH, Ettlingen, 
Germany) at 37°C operating at 1.5 Tesla and 60 MHz proton 
resonance frequency. The longitudinal relaxation times (T
1
) 
and transverse relaxation times (T
2
) were determined at the 
following concentrations for each nanocomposite: 0.01, 
0.03, 0.1, 0.3, 1, and 3 mM Fe in 50% D
2
O/H
2
O. A linear 
regression of the concentration versus T
1
 relaxation time or 
T
2
 relaxation time yielded R
1
 and R
2
 values [mmol−1 s−1], as 
summarized in Table 1.
Table 1 Relaxivity values obtained for Magh, Magh-1-PNPs, and 
Magh-1-PNPs-NODA
Compound R1 
[mmol-1 sec-1]
R2 
[mmol-1 sec-1]
CAN-Magh 0.2 72 H2O/D2O
Magh-1-PNPs 0.9 134 H2O/D2O
Magh-1-PNPs-NODA 0.5 182 H2O/D2O
Abbreviations: PNP, polyethyleneglycol-based nanoparticles; NODA, 
2,2′-(7-(4-((2-aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)
diacetic acid; CAN, ceric ammonium nitrate.
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Radiolabeling of NPs with 68Ga
The 68Ga (T
1/2
 = 68 minutes, β+ = 89%, Electronic Capture 
(EC) = 11%) was obtained from an iThemba 68Ge/68Ga gen-
erator system (IDB Holland bv, Baarle-Nassau, Netherlands) 
with a nominal 68Ge activity of 740 MBq installed at CIC 
biomaGUNE (Guipuzcoa, Spain). The generator was eluted 
with 0.6 M of HCl solution (6 mL). Aqueous HCl solution 
(37%, 2.5 mL) was added to the generator eluate, giving a 
final HCl concentration of 4 M. The resulting solution (total 
volume = 8.5 mL) was passed through a Chromafix® 30-PS-
HCO
3
-anion-exchange column (MACHEREY-NAGEL GmbH 
and Co, Düren, Germany; 45 mg, conditioned sequentially with 
3 mL of purified water and 3 mL of 4 M aqueous HCl solution) 
at a flow rate of 3 mL/minute at room temperature and dried 
under air. The 68Ga was then eluted with 2 mL of purified water 
at a flow rate of 0.7 mL/min and the eluate (∼220 MBq) was col-
lected in a vial precharged with 45 mg of 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES). After the addition 
of 1 M NaOH solution (5–10 µL, final pH = 3.5) to the 68Ga 
eluate, 200 µL of NPs (Magh-1-PNPs-NODA) solution were 
added and the vial, and was heated at 60°C for 30 minutes. 
The reaction crude was cooled at room temperature and 68Ga-
labeled NPs were filtered under centrifugation (10,000 rpm, 
10 minutes) using Amicon® Ultra-4 Centrifugal Filter Units 
(10 kDa, Millipore Corporation). The residue was washed 
twice with HEPES solution (pH = 3.5) and finally suspended 
in physiologic saline solution. All fractions were measured in a 
dose calibrator (CRC® – 25PET Dose Calibrator,  Capintec, Inc, 
Ramsey, NJ). The labeling yield of the NPs was calculated as 
the ratio between the amount of radioactivity in the NPs solu-
tion and the total amount of radioactivity in all fractions.
Quality control of the NPs was performed by thin layer 
chromatography (TLC). A fraction of the NPs solution 
(100 µL) was mixed with a solution containing ethylenedi-
aminetetraacetic acid (EDTA, 1 mg/mL). After shaking for 
10 seconds, 5 µL were deposited on a silica gel 60 F254 plate 
(Macherey-Nagel) and eluted with a mixture of buffered 0.1 M 
aqueous NaOAc solution (pH = 4.5)/0.1 M aqueous EDTA 
solution 90/10. After complete elution, the plates were dried at 
60°C and analyzed using a radio-TLC reader (miniGITA Star, 
Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany) 
and the fractions corresponding to labeled NPs (Rf , 0.1) and 
free gallium (Rf ∼0.35) were quantified. The same analytical 
procedure and conditions were used to assess the stability of 
labeled NPs in physiologic saline solution and in rat serum; 
in this case, the NPs solution was analyzed at different times 
after preparation (15, 30, 60, and 90 minutes).
Toxicity assays
Cell lines
Human PDAC-derived cell lines Panc-1, ASPC-1, MiaPaCa, 
Su86.86, T3M4, BxPC3, and Colo-357 were kindly provided 
by Dr Klaus Felix (University of Heidelberg, Heidelberg, 
Germany). ASPC-1, Su86.86, T3M4, BxPC3, and Colo-
357 cell lines were maintained in culture in Roswell Park 
Memorial Institute medium supplemented with 10% fetal 
bovine serum, L-glutamine, penicillin, and streptomycin. 
Panc-1 and MiaPaCa cell lines were maintained in DMEM 
supplemented with 10% fetal bovine serum, L-glutamine, 
penicillin, and streptomycin.
Viability assay
PDAC cells were seeded in flat-bottom 96-well plates at 
5000 cells/well in a volume of 200 µL of supplemented 
medium. After 72 hours of culture in the presence/absence 
of increasing dosage of Magh-1-PNPs-NODA NPs, 25 µL of 
5 mg/L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich, St Louis, MO) was added 
directly to the cells followed by an additional 4 hours of 
incubation, then 100 µL of DMSO was added. The optical 
density of individual wells was measured at a wavelength of 
550 nm with Infinite® F500 (Tecan Group, Ltd, Mannedorf, 
Switzerland). All assays were performed in triplicate.
Imaging studies
Image acquisition
Male rats weighting 325–375 g (Sprague–Dawley, Harlan 
Laboratories, Udine, Italy) were used to perform PET studies. 
The animals were maintained and handled in accordance with 
the Guidelines for Accommodation and Care of Animals 
(European Convention for the Protection of Vertebrate Ani-
mals Used for Experimental and Other Scientific Purposes) 
and in accordance with internal guidelines, and experimental 
procedures were previously approved by local authorities. 
PET studies were performed using an eXploreVista-CT small 
animal PET-CT system (GE Healthcare, Little Chalfront, 
England). During PET studies, rats were kept normothermic 
using a heating blanket (Homoeothermic Blanket Control 
Unit; Bruker Optik GmbH). Three animals were submitted 
to whole body scans to assess the biodistribution pattern of 
labeled NPs. In all cases, anesthesia was induced with 3% 
isoflurane and maintained by 1.5% to 2% of isoflurane in 
100% O
2
. The tail vein was catheterized with a 24-gauge 
catheter for intravenous administration of 68Ga-labeled NPs 
(7.4 ± 2.4 MBq, corresponding to 3.8 ± 1.3 µg of Fe
2
O
3
, 
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resuspended in 300 µL of physiologic saline solution), which 
was injected concomitantly with the start of a PET dynamic 
acquisition.
Dynamic images (32 frames: 4 × 5 seconds, 4 × 10 seconds, 
6 × 30 seconds, 6 × 60 seconds, 6 × 150 seconds, and 
6 × 300 seconds) were acquired in four bed positions in the 
400–700 keV energetic window, with a total acquisition time 
of 220 minutes. After each PET scan, CT acquisitions were 
also performed providing anatomical information as well 
as the attenuation map for the later image reconstruction. 
Dynamic acquisitions were reconstructed (decay and CT-
based attenuation corrected) with filtered back projection 
using a ramp filter with a cut-off frequency of 1 Hz.
Image analysis
PET images were analyzed using PMOD image analysis 
software (PMOD Technologies Ltd, Zürich, Switzerland). 
Volumes of interest were manually drawn in the lungs, liver, 
kidneys, brain, heart, spleen, bladder, and bone using the CT 
images as anatomical reference. Volumes of interest were 
then transferred to the PET images, and time activity curves 
(decay corrected) were obtained for each organ as cps/cm3. 
Injected dose and organ mass normalizations were finally 
applied to data to get time activity curves as standardized 
uptake values for each organ.
Results and discussion
Chemistry and nanotechnology
In a previous work, the production of hydrophilic water-
compatible maghemite (γ-Fe
2
O
3
) was described.6 Accordingly, 
the experimental conditions did not involve any surface-
passivating bifunctional ligand, nor routinely used physically 
adsorbed natural/nonnatural polymer. More specifically, this 
fabrication process comprises the high-power ultrasonic 
irradiation of preformed 10–15 nanosized magnetite (Fe
3
O
4
) 
NPs together with the strong oxidant ceric  ammonium 
nitrate [CAN, CeIV(NH
4
)
2
(NO
3
)
6
] in a 1/1 v/v acetone/
H
2
O mixture.6 Under these conditions, the simultaneous 
oxidation of the magnetite NPs to maghemite NPs and 
CAN-mediated modification(s) of the NP surface charge/
functionality resulted in crystalline, hydrophilic, and strongly 
positively charged CAN-stabilized maghemite NPs that 
formed extremely stable colloidal water dispersions due to 
electrostatic repulsive interactions. These conditions also 
promote the formation of a polyCOOH-containing organic 
shell on the NP surface, which allows further grafting of 
the particles.11
These NPs have an average hydrodynamic radius of 
44–55 nm (DLS measurements), a ζ potential of ∼40–50 mV, 
and are 8–12 nm in average size as measured from TEM 
(TEM micrograph analysis of more than 100 particulate 
objects). In addition, 57Fe Mössbauer spectroscopy performed 
at 300 K afforded a spectrum that discloses asymmetrical 
sextets of broadened lines that were attributed to significant 
superparamagnetic fluctuations. The NPs superparamag-
netism feature that is essential for MRI application, was also 
confirmed by superconductive quantum interference device.6 
The so-formed CAN-maghemite NPs are water-dispersible, 
and in these conditions (ie, without any surface modification), 
their entrapment into polymeric NPs is rather hard. In order 
to solve this phase compatibility problem, the maghemite NP 
surface was coated by a hydrophobic organic ligand (ethyl 
12-((3,4-dihydroxyphenethyl)amino)-12-oxododecanoate 
(herein referred as ligand 1) specially designed to ensure 
lipophilicity to the iron oxide NPs. Ligand 1 possesses a 
catechol unit at one end, a central aliphatic chain, and a ter-
minal ester group. On the one hand, the catechol unit is well 
known to present a strong affinity to iron due to both the σ 
and π donor power of oxygen atoms.12 On the other hand, the 
aliphatic chain is necessary to confer stability to the systems 
thanks to interchain hydrogen bonding, while the terminal 
ester group should provide good solubility of the NPs in 
common organic solvents. To prove this idea, a solubility test 
of CAN-Magh versus Magh-1 in a water/dichloromethane 
mixture was preformed (see Supplementary Material, Figure 
S6A). As could be expected upon coating of CAN-Magh NPs 
with ligand 1, the NPs readily transferred from the water 
phase to the dichloromethane organic layer.
IR analysis (see Supplementary Material, Figure S5) 
confirmed the successful coating of the maghemite NPs with 
ligand 1: in the region between 3300 and 3500 cm−1, there 
is a strong absorption due to the hydroxyl groups present 
on the surface of the maghemites that make impossible the 
identification of polar organic moieties. However, the stretch-
ing of aliphatic −CH of the ligand can be observed in region 
between 2800 and 3000 cm−1. Furthermore, at 1700 and 
1640 cm−1, the stretching of the two C=O (ester and amide 
groups) can be easily recognized. In addition, thermogravi-
metric analysis confirmed the presence of an organic coating 
of 35.6% in mass (see Figure S3B).
Following our interest in the entrapment of lipophilic 
MNPs,13–15 the hydrophobic Magh-1 NPs were incorporated 
into polymeric micelles using the nanoprecipitation tech-
nique.15,16 The amphiphilic copolymer PLGA-b-PEG-COOH 
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Figure 2 TEM image and relative DLS measurements of Magh-1-PNPs. TEM image (A) and relative DLS measurements (B) of Magh-1-PNPs.
Abbreviations: TEM, transmission electron microscopy; PNPs, polyethyleneglycol-based nanoparticles; DLS, dynamic light scattering.
served as a biocompatible coating that may enable blood 
circulation. Briefly, an acetone solution of Magh-1 and 
copolymer was added dropwise to dd water under vigor-
ous stirring leading to the formation of Magh-1-PNPs. The 
as-synthesized polymeric NPs were characterized by means 
of DLS (Figure 2B). The analysis showed a hydrodynamic 
radius of 95.32 ± 0.88 nm with a polydispersity index (PDI) 
value of 0.153 ± 0.007. The NPs proved to be stable in an 
aqueous environment with a ζ-potential value of −39.2 mV 
at pH = 5.45. TEM observations confirmed the formation of 
polymeric shells around clusters of magh-1 (Figure 2A).
The concentration of iron was investigated by means of 
atomic absorption spectrophotometry, and it was found to 
be 112 ppm.
In order to add the second contrast agent to obtain the 
dual modal imaging platform, the polymeric NP surface was 
functionalized with the 68Ga chelating agent, NODA. The 
carboxylic acid originating from the free end of the PEG 
building block was utilized for this functionalization reaction: 
first, it was activated with 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) in water. In the next step, NODA was 
introduced in the reaction mixture and an amidation reaction 
between the activated acid and NODA amine function occurred. 
The resulting Magh-1-PNPs-NODA possesses a hydrody-
namic radius of 92.34 ± 0.72 nm with a polydispersity index 
value of 0.167 ± 0.011 (DLS analysis), and a ζ-potential value 
of −44 mV at pH = 6.30. The concentration of iron in this case 
was found to be of 134 ppm with a total yield in iron of 64%.
Magh-1-PNPs-NODA in vitro toxicity  
in PDAC-derived cell lines
One potential field of application of 68Ga-labeled NPs is the 
clinical and preclinical diagnosis and evaluation of PDAC, 
which is one of the most deadly tumors, for which detection 
of neoplastic lesions at an early stage might permit life-saving 
interventions.10
Thus, we evaluated the toxicity of Magh-1-PNPs-
NODA NPs on different human PDAC-derived cell lines 
(ASPC-1, Panc-1, MiaPaCa, Su86.86, T3M4, BxPC3, 
Colo-357) using cell growth inhibition assays (MTT test, 
Figure 3 and Figure S1). Magh-1-PNPs-NODA NPs caused 
a modest dose-dependent decrease of cell proliferation.
Despite the fact that a considerable variability among 
cell lines was observed, about a 50% reduction of the pro-
liferation rate was observed within 72 hours of incubation 
0
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Figure 3 Cellular viability rate versus maghemite concentration after 72 hour 
incubation with Magh-1-PNPs-NODA NPs.
Notes: Relative values were normalized to the values from the corresponding 
untreated cells and are shown as percent of survival. Results are expressed as a 
mean percentage of three independent experiments performed in triplicate ± SD.
Abbreviations: NPs, nanoparticles; PNPs, polyethyleneglycol-based nanoparticles; 
NODA, 2,2′-(7-(4-((2-aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-
1,4-diyl)diacetic acid; SD, standard deviation.
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in the majority of the culture cells when 3–6 µg of Fe
2
O
3
 
was present. Notably, at higher concentrations, the Su8686 
cell growth was only marginally affected by Magh-1-PNPs-
NODA NPs.
NMR relaxivity
Although, in general, cells can survive short-term exposure 
to low concentrations of NPs, several groups have found 
cytotoxic effects to emerge in a dose- and time-dependent 
manner for most type of NPs. This is generally due to NP 
internalization inside cells, which elicits inflammatory 
responses, cell-cycle irregularities, and gene expression 
alterations.17 Although a certain extent of Magh-1-PNP-
induced cytotoxicity in the present study occurred, it is 
important to keep in mind that in vitro results can differ 
from what is found in vivo, and that toxicity in vitro may not 
necessarily be clinically relevant. This depends on whether 
repetitive NP administration is required, as well as on the 
NP bioavailability at the target site.
All nanocomposites were very weak T
1
 relaxing agents, 
and as expected for maghemite NPs, they were strong T
2
 
relaxation agents (Table 1). The obtained values indicate 
that the polymer shell enhances R
2
 relaxivity, making the 
NODA functionalized compound ideally suitable as a T
2
/
T
2
* MRI contrast agent.
Radiolabeling of NPs with 68Ga
The attachment of positron emitters to macromolecules is 
usually approached by the chelation of a (positron emitter) 
metallic atom using a bifunctional polyazacarboxylate- or 
tetraaza-macrocycle.18,19 This strategy can be transferred to 
the incorporation of radioisotopes into NPs, because con-
trary to the case of the radio-halogens (eg, 18F), the labeling 
reaction usually takes place under mild conditions without 
damaging the NPs.
A number of metallic PET isotopes have been used to 
date for NP labeling, including 64Cu,20 and 68Ga.21 Copper-64 
has probably been the most widely used due to its relatively 
long half life (12.7 hours), which permits PET evaluation of 
slow biochemical pathways. However, the production of 64Cu 
requires the irradiation of 64Ni with protons, and a laborious 
purification process using anion exchange chromatography.22 
Due to this fact 68Ga, which can be easily obtained from a 
commercially available 68Ge/68Ga generator, is gaining inter-
est in the development of multimodal imaging agents, and its 
incorporation into NPs using bifunctional chelating agents 
has been already reported in the literature.23 In the current 
work, a similar procedure was followed but a preconcentra-
tion step was applied to the 68Ga3+ solution obtained from 
the generator.23 Under optimized experimental conditions 
(T = 60°C, t = 30 minutes, pH = 3.5), the labeling yield of 
Magh-1-PNPs-NODA, as measured by gamma-counting 
after filtration, was 84% ± 6%. Quality control of the NPs 
performed by TLC (Figure 4, red line) showed no peak cor-
responding to free 68Ga after filtration and reconstitution in 
physiologic saline. The stability of labeled NPs in physiologic 
saline solution and in rat serum was also determined by TLC. 
The fraction of free gallium at t = 90 minutes was ,5% in 
both media (not shown in Figure 4). These results confirm 
the stability of the 68Ga-NODA complex, which is very 
appropriate for subsequent in vivo studies.
Imaging studies
In Figure 5A, an image corresponding to the biodistribution 
pattern at long times after administration (frames 10–32) is 
presented. High accumulation in the liver and spleen can 
be visualized. The significant accumulation observed in the 
lungs might suggest the presence of a small percentage of 
aggregates, probably formed after administration of the NPs. 
The significant levels of radioactivity detected in the heart, 
especially at long times after administration of the labeled 
NPs, point towards a slow clearance from the bloodstream 
(Figure 5B). The low level of radioactivity in the bladder (Fig-
ure 5H) indicates a partial (and slow) elimination via urine.
Time–activity curves for the heart, brain, lungs,  kidney, 
spleen, liver, and bladder are shown in Figure 5B to H. 
 Following tail vein injection, dynamic imaging revealed 
a steep peak in the heart, brain, and lungs (Figure 5B–D, 
respectively) as expected from a transient increase in blood 
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Figure 4 TLC profiles obtained for 68Ga-labelled NPs (red line, Rf = 0) and free EDTA-
68Ga complex (black line, Rf = 0.35). 
Note: The complex EDTA-68Ga is generated in situ.
Abbreviations: TLC, thin layer chromatography; NPs, nanoparticles; EDTA, 
ethylenediaminetetra-acetic acid; NODA, 2,2′-(7-(4-((2-aminoethyl)amino)-1-
carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid.
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pool activity. Brain activity decreased to negligible values 
(,0.1% injected dose g−1) 10 minutes after injection; higher 
values were reached in the heart (∼0.25% ID g−1) and lungs 
(∼0.45% ID g−1). Uptake into the spleen (Figure 5F) and liver 
(Figure 5G) was rapid. Within 5 minutes of the appearance 
of radioactivity in the blood, liver, and spleen, levels reached 
a plateau at 1.7% and 2.1%  injected dose g−1, respectively. 
This level was maintained until the end of the study (4 hours 
after administration of NPs).
Accumulation of radioactivity in the bladder (Figure 5H) 
slowly increased along the scan time up to 0.2% ID g−1 at 
the end of the study, while the accumulation of radioactiv-
ity in bones (results not shown) was very low at all times 
(,0.1% of ID/g all along the study). The results obtained 
in the current work demonstrate the suitability of 68Ga-
labelling for subsequent determination of biodistribution 
patterns. Although the NPs described here did not have 
any functionalization to target specific organs or tissues, 
the same labeling and quantification strategy could be 
applied to targeted NPs to assess the potentially selective 
accumulation in specific organs or tumors. Therefore, the 
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Figure 5 PET image and CT time-activity curves of 68Ga. PET image of 68Ga-labeled NPs signal corresponding to averaged time frames at t . 20 minutes after IV injection (A). 
CT images were adjusted on the Y-axis for an appropriate fitting with the tracer distribution. Time-activity curves for heart (B), brain (C), lungs (D), kidneys (E), spleen (F), 
and liver (G) after IV administration of 68Ga-labeled NPs.
Note: Average values +/− standard deviation (n = 3) are shown.
Abbreviations: PET, positron emission tomography; CT, computerized tomography; NPs, nanoparticles; IV, intravenous; ID, injective dose.
NPs presented here are an excellent platform for further 
functionalization in order to become suitable PET/MRI dual 
imaging contrast agents.
Indeed, our in vitro growth inhibition studies indicate an 
IC
50
 value for PDAC cell lines of approximately 3.0–6.0 µg of 
F
2
O
3
 (Figure 3). This is a considerably high value considering 
the dosage of NPs injected in vivo for imaging experiments 
(2.67 µg of F
2
O
3
 injected into animals, Figure 5) suggesting 
a low grade of toxicity of Magh-1-PNPs-NODA NPs. It is 
well known that the physicochemical characteristics of NPs 
are often changed when they come into contact with the blood. 
In particular, NP interactions with proteins in the blood both 
quantitatively and qualitatively affect NP half-lives and biodis-
tribution. Surface protein deposition may induce NP aggrega-
tion, and large aggregates may be trapped in the  capillaries. 
Also, surface opsonization is an issue (ie, the deposition of 
proteins that facilitate NP recognition and clearance from 
the blood by circulating phagocytes or tissue macrophages in 
direct contact with the blood). All these events contribute to 
the reduction of NP bioavailability at the target site. A very 
recent reference discussed these issues.24
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Thus further investigation can be carried out on Magh-
1-PNPs-NODA NPs for the application of such NPs for the 
early diagnosis and evaluation of pancreatic neoplasms.
Conclusion
We have developed a novel multifunctional biocompatible 
hybrid nanocarrier for dual PET/MRI imaging. This nanocar-
rier is composed of a polymer shell containing maghemite 
NPs at its lipophilic core and bearing 68Ga chelating group on 
the outer surface. The T
2
 relaxivity values show promising 
perspectives for the NPs to be used as MRI contrast agents; 
moreover, the incorporation of the positron emitter 68Ga, 
and the stability of the resulting NP-NODA-68Ga complex, 
confirm the suitability of the labeled NPs as contrast agents 
for in vivo PET imaging. The values at which Magh-1-PNPs-
NODA proved to be suitable for MRI/PET analysis were 
found to be not toxic in vitro on seven cell lines of PDAC. 
Thus, the nanoplatform presented here is a promising tool for 
the future development of innovative PET/MRI diagnostic 
agents. Additional applications of this nanocarrier in nano-
medicine are currently under investigation.
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Supplementary materials
1. Derivatization of maghemite NPs with 1,4-diaminobutane 
for Kaiser test
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC), 50 mg (0.26 mmol), was added to 
1 mL of maghemite NPs suspended in doubly distilled water 
(ddH
2
O), and the reaction mixture was shaken for 40 minutes 
at room temperature. Then, the excess of EDC was washed 
out by centrifugation at 8000 rpm (8 minutes, 5°C, three 
times). Then, 1 mL of ddH
2
O and 0.25 mL (3.22 mmol) of 
1,4-diaminobutane were added and the solution was shaken 
for 1.5 hours. The excess of amine was removed by centrifu-
gation at 12,500 rpm (5°C, and three times).25
Results
Kaiser test25 of NPs after surface derivatization with 1,4 
diaminobutane afforded average values of 0.163 mmol 
of accessible COOH/g NPs. ICP measurements: Fe con-
centration was 3.24 mg/mL while Ce concentration was 
1.053 µg/mL (Weight ratio Ce/Fe = 0.000325).
2. Acetyl chloride (20 µL, 0.28 mmol) was added to a 
stirred solution of 12-hydroxydodecanoic acid (1.00 g, 
4.63 mmol) in 40 mL of ethanol under nitrogen 
 atmosphere. The mixture was heated to reflux for 24 hours, 
then, the solvent was removed under vacuum and the 
resulting oil (1.02 g, 4.47 mmol, yield = 90%) was used 
for the next step without further purification.
Hydrogen-1 nuclear magnetic resonance (300 MHz, 
CDCl
3
): δ = 4.09 (q, 2H, CH
2
), 3.59 (t, 2H, CH
2
), 2.23 (t, 2H, 
CH
2
), 1.58 (bs, 6H, CH
2
), 1.25 (bs, 15H, CH
2
 + CH
3
).
Carbon nuclear magnetic resonance: (75 MHz, CDCl
3
): 
δ = 174.023 (C=O), 61.835 (CH
2
), 60.170 (CH
2
), 34.035 
(CH
2
), 32.578 (CH
2
), 29.560 (CH
2
), 29.477 (CH
2
), 29.385 
(2CH
2
), 29.210 (CH
2
), 29.047 (CH
2
), 25.583 (CH
2
), 24.913 
(CH
2
), 14.200 (CH
3
).
3. A suspension of periodic acid (2.13 g, 9.33 mmol) 
in 40 mL of acetonitrile was left to react for 20 min-
utes at room temperature. Then, a solution of ethyl 
12- hydroxydodecanoate (1.02 g, 4.16 mmol) and pyri-
dinium chlorochromate (20 mg, 0.091 mmol) in 10 mL 
of acetonitrile was slowly added, keeping the temperature 
at 0°C with an ice bath. Once completed, the addition the 
ice bath was removed and the mixture was left to react 
for 24 hours at room temperature.
Afterward, 40 mL of ethyl acetate were added, and the mix-
ture was first washed with water (3 × 40 mL), then with an aque-
ous solution of sodium hydrogen sulfate (40% m/V, 3 × 40 mL), 
and finally again with water (2 × 40 mL). The organic phase was 
dried with anhydrous sodium sulfate, and it was filtered and 
evaporated in vacuo to obtain the product as a white solid (1.00 g, 
3.87 mmol, yield = 93%). melting point: 51°C–53°C.
Hydrogen-1 nuclear magnetic resonance (300 MHz, 
CDCl
3
): δ = 4.12 (q, 2H, CH
2
), 2.37 (t, 2H, CH
2
), 2.29 (t, 2H, 
CH
2
), 1.61 (bs, 4H, CH
2
), 1.26 (bs, 15H, CH
2
 + CH
3
).
Carbon nuclear magnetic resonance: (150 MHz, CDCl
3
): 
δ = 180.046 (C=O), 174.003 (C=O), 60.169 (CH
2
), 34.342 
Table S1 Statistical analysis of the mean values reported in 
Figure 3
Cell line P-values
Treatment: Fe2O3 mg/mL
0.75 1.5 3 6
BxPC3 0.010596 0.000987 2.94E-05 0.004902
Colo357 0.007747 0.001283 0.002206 0.000895
MiaPaCa 0.017082 0.000392 0.00308 2.58E-05
Panc1 0.008794 0.01066 0.005601 0.00213
ASPC1 0.012462 0.0272229 0.00528 0.002234
T3M4 0.010854 0.006424 0.002105 0.001432
Su8686 0.108404 0.101878 0.007791 0.001184
Notes: P-values were calculated using a two-sample Student’s t test comparing 
differences in the means between two groups, treated versus untreated, after 72 
hours of culture. P-values ,0.005 were considered statistically significant. Statistically 
significant values are highlighted.
Figure S1 Transmission electron microscopy image of ceric ammonium nitrate 
(CAN)-Magh nanoparticles (NPs).
O
O
HO
Figure S2 Synthesis of ethyl 12-hydroxydodecanoate.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6030
Locatelli et al
International Journal of Nanomedicine 2012:7
(CH
2
), 34.041 (CH
2
), 29.441 (CH
2
), 29.295 (CH
2
), 29.156 
(2CH
2
), 29.060 (CH
2
), 28.987 (CH
2
), 24.918 (CH
2
), 24.625 
(CH
2
), 14.198 (CH
3
).
4. To a stirred solution of 12-ethoxy-12-oxododecanoic 
acid (3.87 mmol, 1.00 g) in 30 mL of anhydrous tetrahy-
drofuran (THF) under nitrogen, 1,1- carbonyldiimidazole 
(6.17 mmol, 0.99 g) was slowly added. The mixture was 
stirred for 1.5 hours, diluted with an additional 70 mL 
of anhydrous THF, and added dropwise (4 hours) to 
a suspension of dopamine hydrochloride (3.87 mmol, 
0.73 g) and pyridine (5.8 mmol, 0.47 mL) in the same 
solvent (30 mL of anhydrous THF), maintaining a 
nitrogen atmosphere. The mixture was left to react 
for 1 hour, and then the solvent was removed under 
vacuum.
The solid was redispersed in ethyl acetate and washed 
three times with water. The organic phase was dried over 
MgSO
4
, filtered and evaporated in vacuo. The crude product 
was then purified with column chromatography (EtOAc/Pet 
ether, 3:1) to provide the final ligand (0.72 g, 1.83 mmol, 
yield = 47%). mp: 60°C–62°C.
Hydrogen-1 nuclear magnetic resonance (300 MHz, 
CDCl
3
): δ = 6.81 (d, 1H, Ar), 6.78 (m, 1H, Ar), 6.59 (d, 1H, 
Ar), 5.65 (bs, 1H, NH), 4.15 (q, 2H, CH
2
), 3.45 (q, 2H, CH
2
), 
2.70 (t, 2H, CH
2
), 2.30 (t, 2H, CH
2
), 2.18 (t, 2H, CH
2
), 1.60 
(bs, 4H, CH
2
), 1.22 (bs, 15H, CH
2
 + CH
3
).
Carbon nuclear magnetic resonance (150 MHz, CDCl
3
): 
δ = 174.538 (C=O), 174.373 (C=O), 144.518 (C), 143.225 
(C), 130.490 (C), 120.373 (CH), 115.479 (CH), 155.183 (CH), 
60.373 (CH
2
), 41.000 (CH
2
), 36.777 (CH
2
), 34.898 (CH
2
), 
34.404 (CH
2
), 29.309 (CH
2
), 29.294 (CH
2
), 29.180 
(CH
2
), 29.115 (2CH
2
), 29.067 (CH
2
), 25.730 (CH
2
), 24.950 
(CH
2
), 14.251 (CH
3
).
Gas chromatography–mass spectrometry ES+: 416 
(M + Na).
Coating of CAN-Magh with ligand
Original CAN-Magh solution (10 mL) was diluted with 
30 mL of water and added to a solution of 1 (300 mg, 
0.762 mmol) in 40 mL of ethanol. The mixture was sonicated 
in an ultrasound bath for 1 hour, and it was left to react 
overnight at room temperature under mechanical stirring. 
Afterward, the solution was decanted magnetically (strong 
external magnet) and the supernatant was removed while 
the brownish solid was washed with ethanol (2 × 30 mL). 
Finally, the solid (Magh-1) was redispersed in 80 mL of 
acetone, sonicated for 30 minutes (bath sonicator, Branson 
Ultrasonics Corporation, Danbury, CT) and immediately 
used in the following steps.
5. Poly(D,L-lactide-co-glycolide)-block-poly(ethylene 
glycol) was synthesized through the activation of 
 carboxyl- capped PLGA-COOH (MW ∼7 kDa) with 
N-hydroxysuccinimide using dicyclohexylcarbodiimide 
coupling chemistry, and then conjugated to the amine 
bifunctional NH
2
-PEG-COOH (MW ∼3 kDa), in chloroform 
and in the presence of N,N-Diisopropylethylamine.15
6. Synthesis of Magh-1-PNPs-NODA
The linkage of 2,2′-(7-(4-((2-aminoethyl)amino)-1-
carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic 
acid (NODA) on the surface of the particle was carried out 
through a classic peptide formation. In particular, 35 mL of 
a 0.28 mM Magh-1-polyethyleneglycol-based nanoparticle 
water solution (0.010 mmol of D,L-lactide-co-glycolide)-
block-poly(ethylene glycol) were stirred for 2 hours in the 
presence of 0.010 mmol of 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide (1.7 mL of a 5.7 mM water solution 
neutralized with 0.1 M HCl solution up to pH = 7.60). Then, 
0.010 mmol of NODA-GA-ethylenediamine was added 
(6.1 mL of a 1.6 mM water solution neutralized with 0.1 M 
NaOH solution up to pH = 7.15) and the reaction mixture 
was kept under stirring for additional 2 hours. The particles 
were purified with a centrifugal filter device (Amicon Ultra, 
Ultracel membrane with 100.000 normal molecular weight 
limit; Millipore Corporation, Billerica, MA) and redispersed 
in 25 mL of water.
7. Synthesis of Magh-1-PNPs-NODA
The linkage of 2,2′-(7-(4-((2-aminoethyl)amino)-1-
carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic 
acid (NODA) on the surface of the particle was carried 
out through a classic peptide formation. In particular, 
35 mL of a 0.28 mM Magh-1-polyethyleneglycol-based 
polymeric nanoparticle water solution (0.010 mmol of 
poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol)) 
was stirred for 2 hours in the presence of 0.010 mmol of 
O
OH
O
O
Figure S3 Synthesis of 12-ethoxy-12-oxododecanoic acid.
H
N O
O
O
HO
HO
Figure S4 Synthesis of ethyl 12-((3,4-dihydroxyphenethyl)amino)-12-oxododecanoate 
(EDAO, 1).
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Figure S5 Infrared spectra of ceric ammonium nitrate (CAN)-Magh (black line) and Magh-1 (blue line).
Abbreviation: T, transmittance.
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Figure S7 Synthesis of Magh-1-PNPs-NODA.
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Figure S6 Solubility test of ceric ammonium nitrate (CAN)-Magh versus Magh-1 (A) and thermogravimetric analysis of Magh-1 (B).
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1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.7 mL 
of a 5.7 mM water solution neutralized with 0.1 M HCl 
solution up to pH = 7.60). Then, 0.010 mmol of NODA-GA- 
ethylenediamine was added (6.1 mL of a 1.6 mM water solu-
tion neutralized with 0.1 M NaOH solution up to pH = 7.15), 
and the reaction mixture was kept under stirring for additional 
2 hours. The particles were purified with a centrifugal filter 
device (Amicon Ultra, Ultracel membrane with 100.000 nor-
mal molecular weight limit; Millipore Corporation,  Billerica, 
MA) and redispersed in 25 mL of water.
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